Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...
In February 2024, Novo partnered with US-based biotech Neomorph in a collaboration and licensing agreement to discover and develop multiple molecular glue degraders for cardiometabolic disorders and ...